article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. Branded drugs, developed through extensive research and clinical trials, often enjoy patent protection for a limited period.

article thumbnail

The Future of Generic Drug Development for Emerging Markets: Opportunities and Challenges

Drug Patent Watch

The Future of Generic Drug Development: Opportunities and Challenges for Emerging Markets As the global healthcare landscape continues to evolve, emerging markets are playing an increasingly important role in shaping the future of generic drug development. Share your thoughts in the comments below! Read the full article here: [link]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovative Approaches to Generic Drug Development: Case Studies

Drug Patent Watch

Why Generic Drugs Matter Generic drugs are the Robin Hoods of the pharmaceutical world, stealing from the rich (brand-name drugs) and giving to the poor (our wallets). They offer the same therapeutic benefits as their brand-name counterparts but at a fraction of the cost. But how do companies develop these cost-effective alternatives?

article thumbnail

FDA approves new CAR-T competitor to Gilead’s Tecartus

Bio Pharma Dive

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the brand name Aucatzyl.

article thumbnail

Sanofi, expanding in radiopharma, strikes a joint venture deal

Bio Pharma Dive

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for cancer under the Orano Med brand.

Branding 282
article thumbnail

Sanofi unveils global health brand for medicines supply

Pharmaceutical Technology

Sanofi has unveiled the global health brand, Impact, to make available standard of care treatments for non-profit supply to at-risk populations in low-income countries. The introduction of the Impact brand is one of the steps adopted since the formation of Sanofi Global Health last year.

Branding 147
article thumbnail

EQRx builds cancer drug pipeline as plans to challenge big pharma take shape

Bio Pharma Dive

The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.

Licensing 274